Evaluation of Pathologic Complete Response (pCR) to Neoadjuvant Chemotherapy in Iranian Breast Cancer Patients with Estrogen Receptor Positive and HER2 Negative and impact of predicting variables on pCR.
Ramesh OmranipourRoghiyeh JaliliAdel YazdankhahkenaryAbdolali AssarianMehrzad MirzaniaBita EslamiPublished in: European journal of breast health (2020)
The pCR rate after NAC in ER+/HER2- subtypes of breast cancer is low. Therefore, the optimal therapy for these patients should be further investigated.
Keyphrases
- neoadjuvant chemotherapy
- estrogen receptor
- locally advanced
- end stage renal disease
- ejection fraction
- lymph node
- chronic kidney disease
- sentinel lymph node
- newly diagnosed
- transcription factor
- prognostic factors
- real time pcr
- peritoneal dialysis
- squamous cell carcinoma
- early stage
- rectal cancer
- high resolution
- young adults
- mass spectrometry
- patient reported outcomes
- single molecule
- high speed